DEVELOPING TRUE
PAN-CANCER DETECTION
ONE BLOOD TEST
FOR ALL TYPES OF CANCER
At Binary Genomics, we are taking a fundamentally more inclusive approach to cancer detection. Our DNA-based blood test dynamically adapts to capture unique epigenetic fingerprints from each patient’s tumor, regardless of cancer type.
Our unbiased approach efficiently detects signals from all cancers, including lower-prevalence cancers that are often deprioritized in other tests.
Our Solution
Gene silencing by methylation of promoters is a key mechanism of carcinogenesis.
Binary Genomics’ proprietary technology captures abnormally methylated promoter DNA fragments based on their high methylation density, not based on pre-specified sequence.
In this way, gene silencing events are detected wherever they occur in a cancer cell’s genome, from any cancer in any patient.
A Versatile Platform
Designed with inherent flexibility, our technology can inform several phases of the cancer journey.
We are pursuing applications to enable earlier cancer diagnosis, surveillance of residual or recurrent disease, and real-time monitoring of treatment efficacy.
Ultimately, we seek to deliver a broad-spectrum diagnostic tool to improve patient outcomes.
Leadership Team
-
Michael T. Barrett, Ph.D.
Associate Professor of Pharmacology
Mayo Clinic College of Medicine
CO-FOUNDER and CEO
-
Abhijit A. Patel, MD, PhD
Associate Professor of Therapeutic Radiology
Yale University School of Medicine
CO-FOUNDER
-
Mitesh J. Borad, MD
Professor of Medicine (Medical Oncology)
Mayo Clinic College of Medicine
CO-FOUNDER